Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

1 week ago 27

Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fatal liver disease.

Read Entire Article

Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

Related

Here’s what really matters for Amazon’s stock — beyond the A...

Can AMD’s stock live up to the hype? Depends on how you look...

Rivian’s stock could fall more than 20% as the sales outlook...

Trending

Popular

Why your stock and bond index funds outsmart managers of col...

Wall Street’s ‘fear gauge’ surges to highest level since May...

How low can Bitcoin price go if $110K BTC support fails?

The cheapest ticket to see Team USA play in the FIFA World C...

Monad Opens Airdrop Portal Ahead of Token Launch